RESUMEN
For volumetric reconstruction of the refractive index field in a flow, background-oriented schlieren (BOS) imaging which measures the deflection of light rays due to refractive index variations is combined with an evolutionary tomographic algorithm for the first time, called evolutionary BOS tomography (EBOST). In this work application to reactive flows is presented. Direct non-linear ray-tracing of the reconstruction domain is used to evaluate the fitness of solution candidates during the evolutionary strategy that was implemented to run on a multi-GPU system. The use of a diversity measure and its consideration in a migration policy was tested against a simple scheme that distributes the best chromosome (solution candidate) in an island-based genetic algorithm. The extensive set of control parameters of the presented algorithm was harnessed by a self-adaptive strategy taking into account the fitness function and operator rates. Quantitative characterisation of the EBOST via numerical phantom studies, using flame simulations as ground truth data is presented. A direct comparison to a state-of-the-art BOST algorithm demonstrates similar accuracy for a turbulent swirl flame phantom reconstruction. A series of experimental applications of the EBOST on several unsteady and turbulent flames is also presented. In all cases, the instantaneous and time-averaged flame structure is revealed, proving the benefit of EBOST for volumetric flow diagnostics.
RESUMEN
Tomographic imaging using multi-simultaneous measurements (TIMes) of spontaneous light emission was performed on various operating conditions of the SpraySyn burner to analyse the flame morphology and its potential impact on spray flame pyrolysis. Concurrent instantaneous and time-averaged three-dimensional measurements of CH* chemiluminescence (flame front indicator) and atomic Na emission from NaCl dissolved in the injected combustible liquid (related to hot burnt products of the spray flame) were reconstructed employing a 29-camera setup. Overlapping regions of CH* and Na are presented using isosurface visualisation, local correlation coefficient fields and joint probability distributions. The instantaneous results reveal the complex nature of the reacting flow and regions of interaction between the flame front with the hot gases that originate from the spray stream. The averaged reconstructions show that the spray flames tested are slightly asymmetric near the burner exit but develop into symmetric bell-shaped distributions at downstream locations. The changes in the flame structure for different operating conditions are analysed in light of previous studies, helping in the better understanding of the nanoparticle synthesis process. Furthermore, the importance of using measurements from two views for significantly improved alignment of the burner based on the originally proposed procedure are discussed in light of the reconstructions. This is an important aspect since the SpraySyn is intended for use as a well-defined standardised burner for nanoparticle synthesis, which is being investigated numerically and experimentally across different research groups.
RESUMEN
The method of tomographic imaging using multi-simultaneous measurements (TIMes) for flame emission reconstructions is presented. Measurements of the peak natural CH* chemiluminescence in the flame and luminescence from different vaporised alkali metal salts that were seeded in a multi-annulus burner were used. An array of 29 CCD cameras around the Cambridge-Sandia burner was deployed, with 3 sets of cameras each measuring a different colour channel using bandpass optical filters. The three-dimensional instantaneous and time-averaged fields of the individual measured channels were reconstructed and superimposed for two new operating conditions, with differing cold flow Reynolds numbers. The contour of the reconstructed flame front followed the interface between the burnt side of the flame, where the alkali salt luminescence appears, and the cold gas region. The increased mixing between different reconstructed channels in the downstream direction that is promoted by the higher levels of turbulence in the larger Reynolds number case was clearly demonstrated. The TIMes method enabled combustion zones originating from different streams and the flame front to be distinguished and their overlap regions to be identified, in the entire volume.
RESUMEN
BACKGROUND & AIMS: Recently, overexpression of the fibroblast growth factor receptor 3 (FGFR3) splice variants FGFR3-IIIb and FGFR3-IIIc was found in ~50% of hepatocellular carcinoma (HCC). Here, we aim to identify FGFR3-IIIb/IIIc ligands, which drive the progression of HCC. METHODS: FACS, MTT assay and/or growth curves served to identify the FGFR3-IIIb/IIIc ligand being most effective to induce growth of hepatoma/hepatocarcinoma cell lines, established from human HCC. The most potent FGF was characterized regarding the expression levels in epithelial and stromal cells of liver and HCC and impact on neoangiogenesis, clonogenicity and invasive growth of hepatoma/hepatocarcinoma cells. RESULTS: Among all FGFR3-IIIb/IIIc ligands tested, FGF9 was the most potent growth factor for hepatoma/hepatocarcinoma cells. Replication and/or sprouting of blood/lymphendothelial cells was stimulated as well. FGF9 occurred mainly in stromal cells of unaltered liver but in epithelial cells of HCC. Every fifth HCC exhibited overexpressed FGF9 and frequent co-upregulation of FGFR3-IIIb/IIIc. In hepatoma/hepatocarcinoma cells FGF9 enhanced the capability for clonogenicity and disintegration of the blood and lymphatic endothelium, being most pronounced in cells overexpressing FGFR3-IIIb or FGFR3-IIIc, respectively. Any of the FGF9 effects in hepatoma/hepatocarcinoma cells was blocked completely by applying the FGFR1-3-specific tyrosine kinase inhibitor BGJ398 or siFGFR3, while siFGFR1/2/4 were mostly ineffective. CONCLUSIONS: FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.